GO:0016234 inclusion body: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016234 (inclusion body) is a cellular component defined as a discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers.
• Inclusion bodies are best known as misfolded protein aggregates in bacteria such as Escherichia coli, where they form during recombinant protein overexpression and require solubilization and refolding for recovery.
• In human disease, inclusion bodies are pathological hallmarks of inclusion body myositis, where rimmed vacuoles and amyloid-like deposits accumulate in muscle fibers.
• The term also covers neuronal cytoplasmic inclusions, linking it to neurodegenerative protein aggregation biology.
• Research on inclusion bodies spans microbiology, protein biochemistry, and clinical neurology, making it a cross-disciplinary GO term.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of genes that drive or clear inclusion body formation.
Description
GO:0016234, inclusion body, is a cellular component term in the Gene Ontology that describes a discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers. This definition captures a wide range of biological structures, from bacterial protein aggregates that form during recombinant expression to pathological inclusions in human muscle and neurons. The term is therefore central to both biotechnology and disease biology. In bacterial systems, inclusion bodies are dense, refractile particles composed largely of misfolded recombinant protein, and their formation is a major bottleneck in producing soluble, active proteins. In clinical neuroscience and rheumatology, inclusion bodies are diagnostic and pathogenic features of inclusion body myositis, a chronic inflammatory myopathy characterized by rimmed vacuoles and protein aggregates in muscle fibers. Because inclusion bodies can be either a manufacturing challenge or a disease hallmark, researchers need precise models and methods to study their composition, assembly, and clearance. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0016234, its associated genes, disease links, and experimental approaches including CRISPR-based cell models.
inclusion body At A Glance
| GO ID | GO:0016234 |
|---|---|
| GO term | inclusion body |
| Ontology | cellular_component |
| Synonym | cellular inclusion; neuronal cytoplasmic inclusion |
| Definition | A discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers. |
| Major function | Sequestration of aggregated proteins or biopolymers; can be protective, pathological, or a recombinant protein production intermediate. |
| Disease relevance | Inclusion body myositis; neuronal cytoplasmic inclusions in neurodegeneration. |
| Biotechnological relevance | Bacterial inclusion bodies in E. coli require solubilization and refolding for protein recovery. |
| Research methods | Microscopy, proteomics, solubilization/refolding assays, and CRISPR-based gene editing models. |
What Is GO:0016234?
According to the Gene Ontology, GO:0016234 (inclusion body) is a cellular component defined as a discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers. In practice, this means any membrane-free, microscopically visible aggregate inside a cell that arises when proteins or other macromolecules self-associate into a stable, often insoluble structure. The synonym cellular inclusion reflects this general meaning, while neuronal cytoplasmic inclusion highlights a specific disease-relevant context. Inclusion bodies are not membrane-bound organelles; they are dynamic aggregates that can be composed of misfolded proteins, amyloid-like fibrils, or other biopolymers.
Why Is inclusion body Important in Cell Biology?
GO:0016234 is important because inclusion bodies sit at the intersection of protein quality control, biotechnology, and human disease. In recombinant protein production, the formation of inclusion bodies in Escherichia coli is a common outcome of high-level expression, and recovering active protein requires solubilization and refolding strategies. In medicine, inclusion bodies are pathological hallmarks of inclusion body myositis, a progressive muscle disease with characteristic rimmed vacuoles and protein aggregates. The term also encompasses neuronal cytoplasmic inclusions, which are relevant to neurodegenerative protein aggregation. Understanding the genes and mechanisms that drive inclusion body formation can therefore inform both bioprocess optimization and therapeutic development.
• Inclusion bodies are a major bottleneck in recombinant protein production, requiring solubilization and refolding for recovery of active protein.
• They are diagnostic and pathogenic features of inclusion body myositis, a chronic inflammatory myopathy.
• The term includes neuronal cytoplasmic inclusions, linking it to neurodegenerative protein aggregation.
• Bacterial inclusion body purification methods are well established and enable controlled study of aggregate composition.
• Mild solubilization processes have been developed to improve recovery of bioactive proteins from E. coli inclusion bodies.
• Inclusion body formation reflects protein misfolding and quality control pathways that are conserved across systems.
• CRISPR models allow causal testing of genes that promote or prevent inclusion body formation.
• The term is cross-disciplinary, relevant to microbiology, protein biochemistry, and clinical neurology.
What Happens During inclusion body?
Protein aggregation and misfolding
In simple terms: When proteins are made too fast or fold incorrectly, they can stick together into clumps called inclusion bodies.
Inclusion bodies form when proteins or other biopolymers aggregate into discrete intracellular structures. In bacterial expression systems, high-level synthesis of recombinant proteins can overwhelm folding pathways, leading to the accumulation of misfolded protein in inclusion bodies. These aggregates are not simply inert; they represent a specific cellular state that can be studied biochemically and structurally.
Solubilization and refolding
In simple terms: To get usable protein out of inclusion bodies, scientists must first dissolve the clump and then help the protein fold back correctly.
Recovery of active protein from inclusion bodies requires solubilization followed by refolding. Solubilization and refolding protocols have been developed for bacterial inclusion body proteins, and mild solubilization processes can improve yields of bioactive protein. These methods are essential for biotechnological applications and for studying the proteins that constitute inclusion bodies.
Purification of inclusion bodies
In simple terms: Inclusion bodies can be isolated from cells so researchers can study what they are made of.
Bacterial inclusion body purification methods allow isolation of these aggregates for downstream analysis. Purification enables compositional studies, including identification of the proteins and other biopolymers that make up the inclusion body. This is a key step for both basic research and industrial process development.
Pathological inclusion formation in muscle
In simple terms: In inclusion body myositis, muscle cells accumulate clumps of protein that damage the fibers.
In inclusion body myositis, muscle fibers develop rimmed vacuoles and protein aggregates that are characteristic of the disease. These inclusions are a defining pathological feature and contribute to muscle weakness and degeneration. The presence of inclusion bodies in muscle biopsies is used in diagnosis and is an active area of research.
Neuronal cytoplasmic inclusions
In simple terms: Nerve cells can also form inclusion bodies, which are seen in some neurodegenerative conditions.
The synonym neuronal cytoplasmic inclusion reflects the occurrence of inclusion bodies in neurons. These structures are relevant to neurodegenerative protein aggregation and are studied as markers of cellular stress and dysfunction. The GO term therefore covers both bacterial and human inclusion bodies, unifying diverse biological contexts.
Key Genes Involved in GO:0016234 inclusion body
The following genes and proteins are associated with inclusion body biology, including bacterial aggregation, muscle pathology, and neuronal inclusions, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SQSTM1 | Autophagy receptor involved in protein aggregate clearance | Studied in inclusion body myositis and neurodegeneration |
| VCP | AAA-ATPase in protein quality control | Mutations linked to inclusion body myopathy and neurodegeneration |
| TARDBP | RNA-binding protein forming neuronal inclusions | Relevant to neuronal cytoplasmic inclusions |
| APP | Amyloid precursor protein | Amyloid-like deposits in inclusion body myositis |
| BAG3 | Co-chaperone in protein quality control | Associated with myofibrillar myopathy and protein aggregation |
| CRYAB | Small heat shock protein | Chaperone that prevents protein aggregation |
| DES | Muscle intermediate filament protein | Aggregates in muscle proteinopathies |
| MYH2 | Myosin heavy chain | Muscle fiber protein relevant to inclusion body myositis |
| GNE | UDP-GlcNAc 2-epimerase | Mutations cause GNE myopathy with rimmed vacuoles |
| HSPB8 | Small heat shock protein | Chaperone involved in protein aggregate handling |
| OPTN | Autophagy receptor | Linked to protein aggregate clearance |
| TBK1 | Kinase in autophagy and inflammation | Associated with inclusion body myositis and neurodegeneration |
| C9orf72 | Gene with repeat expansions | Forms neuronal inclusions in ALS/FTD |
| FUS | RNA-binding protein | Forms neuronal cytoplasmic inclusions |
| SOD1 | Superoxide dismutase 1 | Aggregates in ALS models |
| HTT | Huntingtin | Forms inclusion bodies in Huntington disease |
| LAMP2 | Lysosomal membrane protein | Autophagy dysfunction linked to inclusion formation |
| TFEB | Transcription factor for autophagy | Regulates clearance of protein aggregates |
How Is inclusion body Regulated?
Inclusion body formation and clearance are regulated by protein quality control pathways, including chaperones and autophagy. In inclusion body myositis, dysregulation of autophagy and protein degradation contributes to the accumulation of inclusion bodies. The transcription factor TFEB regulates autophagy and lysosomal biogenesis, influencing the clearance of protein aggregates. Chaperones such as CRYAB and HSPB8 help prevent protein aggregation, and their dysfunction can promote inclusion formation. In bacterial systems, expression conditions such as temperature and induction strength influence inclusion body formation, and refolding protocols can be optimized to recover active protein.
inclusion body and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SQSTM1 | Inclusion body myositis; autophagy dysfunction | Knockout cell model to study aggregate clearance |
| VCP | Inclusion body myopathy; neurodegeneration | Point mutation knock-in to model disease variants |
| TARDBP | Neuronal cytoplasmic inclusions in ALS/FTD | Overexpression of mutant TARDBP in neuronal cells |
| APP | Amyloid-like deposits in inclusion body myositis | Knock-in of APP mutations to study aggregation |
| HTT | Huntington disease inclusion bodies | Knock-in of expanded polyQ repeats |
Inclusion body myositis
Inclusion body myositis is a chronic inflammatory myopathy characterized by progressive muscle weakness and the presence of rimmed vacuoles and protein aggregates in muscle fibers. The disease was described in early case series and remains a distinct clinical entity. Inclusion bodies in muscle biopsies are a hallmark of the disease and are used in diagnosis. The pathogenesis involves both inflammatory and degenerative mechanisms, with protein aggregation playing a central role.
Neurodegenerative protein aggregation
Neuronal cytoplasmic inclusions are a feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis and frontotemporal dementia. Proteins such as TARDBP, FUS, and C9orf72-derived dipeptide repeats form inclusions that are toxic to neurons. The GO term inclusion body encompasses these structures, linking them to a broader biology of protein aggregation.
Bacterial inclusion bodies in biotechnology
In Escherichia coli, inclusion bodies form during overexpression of recombinant proteins and are a major challenge for producing soluble, active proteins. Solubilization and refolding methods have been developed to recover functional protein from these aggregates. Purification of inclusion bodies is a standard step in bioprocess development.
From inclusion body-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase inclusion body formation? | Knockout cell model |
| Does a disease-associated point mutation alter aggregation? | Point mutation knock-in |
| Can a tagged protein be used to track inclusion bodies? | Tagged knock-in |
| Does overexpression of a gene drive inclusion body formation? | Overexpression cell model |
| Which genes are required for inclusion body clearance? | CRISPR library screening |
| What is the proteomic composition of inclusion bodies? | Purification followed by mass spectrometry |
How to Study the inclusion body Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Electron microscopy | Ultrastructure of inclusion bodies | Visualizing aggregates in muscle or bacteria |
| Immunofluorescence | Protein composition of inclusions | Identifying TARDBP or APP in inclusions |
| Inclusion body purification | Isolation of aggregates | Biochemical analysis of bacterial inclusion bodies |
| Solubilization and refolding | Recovery of active protein | Biotechnological production from E. coli |
| Mass spectrometry | Proteomic composition | Identifying proteins in inclusion bodies |
| CRISPR knockout | Gene function in aggregation | Testing candidate genes for inclusion body formation |
| CRISPR knock-in | Disease variant effects | Modeling point mutations linked to inclusion body myositis |
| Overexpression | Gain-of-function aggregation | Driving inclusion body formation in cell models |
Microscopy and imaging
Inclusion bodies can be visualized by light and electron microscopy, and in muscle biopsies they appear as rimmed vacuoles and protein aggregates. Immunofluorescence with antibodies against proteins such as TARDBP or APP can identify the composition of inclusions.
Protein purification and refolding
Bacterial inclusion bodies can be purified and then solubilized and refolded to recover active protein. These methods are essential for characterizing the proteins that form inclusion bodies and for biotechnological production.
Proteomics and biochemical analysis
Mass spectrometry and biochemical assays can identify the protein and biopolymer components of inclusion bodies. Solubilization and refolding studies provide insight into the stability and folding of aggregated proteins.
CRISPR-based functional studies
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in inclusion body formation and clearance. These approaches can be combined with imaging and proteomics to dissect mechanisms.
How CRISPR Can Be Used to Study GO:0016234 inclusion body
Knockout
CRISPR knockout cell models can be used to test whether loss of a candidate gene, such as SQSTM1 or VCP, alters inclusion body formation or clearance. These models help establish causal roles for genes implicated in protein aggregation.
Point Mutation
Point mutation knock-in models can replicate disease-associated variants, such as those in VCP or GNE, to study their impact on inclusion body formation and muscle cell pathology.
Knock-in
Tagged knock-in models allow endogenous proteins to be tracked and their incorporation into inclusion bodies to be monitored in real time. This is valuable for studying the dynamics of aggregate assembly.
Overexpression
Overexpression of aggregation-prone proteins, such as TARDBP or HTT, can drive inclusion body formation in cell models, enabling studies of toxicity and clearance mechanisms.
How EDITGENE Supports inclusion body Research
Researchers studying inclusion body-related genes often need to determine whether a candidate gene is causally involved in aggregate formation, clearance, or disease pathology. CRISPR-based cell models provide a precise way to manipulate genes and test these hypotheses in relevant cellular contexts.
Contact EDITGENE today to design your custom CRISPR model for inclusion body research.
Frequently Asked Questions About inclusion body
What is an inclusion body (GO:0016234)?
An inclusion body is a discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers, as defined by the Gene Ontology.
What genes are involved in inclusion body formation?
Genes such as SQSTM1, VCP, TARDBP, APP, and HTT have been implicated in inclusion body biology in muscle and neuronal contexts.
What is inclusion body myositis?
Inclusion body myositis is a chronic inflammatory myopathy characterized by progressive muscle weakness and rimmed vacuoles with protein aggregates in muscle fibers.
How are bacterial inclusion bodies purified?
Bacterial inclusion bodies can be purified using established methods, followed by solubilization and refolding to recover active protein.
Why do inclusion bodies form in E. coli?
Inclusion bodies often form during high-level recombinant protein expression when folding pathways are overwhelmed, leading to misfolded protein aggregation.
What is the difference between inclusion bodies and aggresomes?
The GO term inclusion body covers discrete intracellular aggregates of proteins or biopolymers; aggresomes are a specific type of inclusion body formed at the microtubule-organizing center.
Can CRISPR be used to study inclusion bodies?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to test gene function in inclusion body formation and clearance.
What methods are used to study inclusion bodies?
Methods include electron microscopy, immunofluorescence, inclusion body purification, solubilization and refolding, mass spectrometry, and CRISPR-based functional assays.
Are inclusion bodies always harmful?
Not necessarily; in bacteria they can be a production intermediate, while in human disease such as inclusion body myositis they are pathological.
What is the role of autophagy in inclusion body clearance?
Autophagy pathways, regulated by genes such as SQSTM1 and TFEB, help clear protein aggregates, and their dysfunction can lead to inclusion body accumulation.
Conclusion
GO:0016234 (inclusion body) is a cellular component term that unifies diverse biological phenomena, from bacterial protein aggregates to pathological inclusions in muscle and neurons. Its definition as a discrete intracellular part formed of aggregated molecules highlights the common principle of protein self-association. Research on inclusion bodies has direct implications for biotechnology, where solubilization and refolding are required for protein recovery, and for medicine, where inclusions are hallmarks of diseases such as inclusion body myositis. CRISPR-based models and advanced imaging and proteomic methods provide powerful tools to dissect the genes and mechanisms that drive inclusion body formation and clearance.
References
- 1. Greenberg SA. 2019. Inclusion body myositis: clinical features and pathogenesis.. Nat Rev Rheumatol 15(5):257-272 PMID: 30837708
- 2. Singh SM et al.. 2005. Solubilization and refolding of bacterial inclusion body proteins.. J Biosci Bioeng 99(4):303-10 PMID: 16233795
- 3. Seras-Franzoso J et al.. 2015. Bacterial inclusion body purification.. Methods Mol Biol 1258:293-305 PMID: 25447871
- 4. Singh A et al.. 2015. Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process.. Microb Cell Fact 14:41 PMID: 25889252
- 5. Tomé FM et al.. 1981. Inclusion body myositis.. Acta Neuropathol Suppl 7:287-91 PMID: 6261517
- 6. Calabrese LH et al.. 1994. Inclusion body myositis.. Rheum Dis Clin North Am 20(4):955-72 PMID: 7855331
- 7. Yunis EJ et al.. 1971. Inclusion body myositis.. Lab Invest 25(3):240-8 PMID: 5095321
- 8. Burgess RR. 2009. Refolding solubilized inclusion body proteins.. Methods Enzymol 463:259-82 PMID: 19892177
